Literature DB >> 12615169

Neurodevelopmental disorders in males related to the gene causing Rett syndrome in females (MECP2).

Ute Moog1, Eric E J Smeets, Kees E P van Roozendaal, Sam Schoenmakers, Jos Herbergs, Anneke M J Schoonbrood-Lenssen, Connie T R M Schrander-Stumpel.   

Abstract

Mutations in the MECP2 (methyl-CpG-binding protein 2) gene are known to cause Rett syndrome, a well-known and clinically defined neurodevelopmental disorder. Rett syndrome occurs almost exclusively in females and for a long time was thought to be an X-linked dominant condition lethal in hemizygous males. Since the discovery of the MECP2 gene as the cause of Rett syndrome in 1999, MECP2 mutations have, however, also been reported in males. These males phenotypically have classical Rett syndrome when the mutation arises as somatic mosaicism or when they have an extra X chromosome. In all other cases, males with MECP2 mutations show diverse phenotypes different from classical Rett syndrome. The spectrum ranges from severe congenital encephalopathy, mental retardation with various neurological symptoms, occasionally in association with psychiatric illness, to mild mental retardation only. We present a 21-year-old male with severe mental retardation, spastic tetraplegia, dystonia, apraxia and neurogenic scoliosis. A history of early hypotonia evolving into severe spasticity, slowing of head growth, breathing irregularities and good visual interactive behaviour were highly suggestive of Rett syndrome. He has a de novo missense mutation in exon 3 of the MECP2 gene (P225L). The clinical spectrum and molecular findings in males with MECP2 mutations are reviewed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615169     DOI: 10.1016/s1090-3798(02)00134-4

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  18 in total

Review 1.  Brief report: systematic review of Rett syndrome in males.

Authors:  Brian Reichow; Annie George-Puskar; Tara Lutz; Isaac C Smith; Fred R Volkmar
Journal:  J Autism Dev Disord       Date:  2015-10

Review 2.  Rett syndrome and other autism spectrum disorders--brain diseases of immune malfunction?

Authors:  N C Derecki; E Privman; J Kipnis
Journal:  Mol Psychiatry       Date:  2010-02-23       Impact factor: 15.992

Review 3.  Rett syndrome: clinical review and genetic update.

Authors:  L S Weaving; C J Ellaway; J Gécz; J Christodoulou
Journal:  J Med Genet       Date:  2005-01       Impact factor: 6.318

4.  Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.

Authors:  Christopher A Chapleau; Gaston D Calfa; Meredith C Lane; Asher J Albertson; Jennifer L Larimore; Shinichi Kudo; Dawna L Armstrong; Alan K Percy; Lucas Pozzo-Miller
Journal:  Neurobiol Dis       Date:  2009-05-12       Impact factor: 5.996

5.  The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2.

Authors:  Jeffrey L Neul; Timothy A Benke; Eric D Marsh; Steven A Skinner; Jonathan Merritt; David N Lieberman; Shannon Standridge; Timothy Feyma; Peter Heydemann; Sarika Peters; Robin Ryther; Mary Jones; Bernhard Suter; Walter E Kaufmann; Daniel G Glaze; Alan K Percy
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2018-12-07       Impact factor: 3.568

Review 6.  Rett syndrome and MeCP2.

Authors:  Vichithra R B Liyanage; Mojgan Rastegar
Journal:  Neuromolecular Med       Date:  2014-03-11       Impact factor: 3.843

Review 7.  MECP2 mutations in males.

Authors:  Laurent Villard
Journal:  J Med Genet       Date:  2007-03-09       Impact factor: 6.318

8.  Adult Phenotypes in Angelman- and Rett-Like Syndromes.

Authors:  M H Willemsen; J H M Rensen; H M J van Schrojenstein-Lantman de Valk; B C J Hamel; T Kleefstra
Journal:  Mol Syndromol       Date:  2012-01-13

9.  Rett Syndrome.

Authors:  E E J Smeets; K Pelc; B Dan
Journal:  Mol Syndromol       Date:  2012-04-16

10.  Variable phenotypic expression of a MECP2 mutation in a family.

Authors:  Kimberly Augenstein; Jane B Lane; Antony Horton; Carolyn Schanen; Alan K Percy
Journal:  J Neurodev Disord       Date:  2009-12       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.